• In June 2026, Siegwerk Druckfarben AG & Co. KGaA announced a collaboration with Celanese Corporation to use Celanese’s 50% bio-based ethyl acetate as a drop-in solvent for printing inks, enabling more sustainable packaging solutions without altering existing manufacturing processes.
• This partnership underscores how Celanese’s bio-based acetyl chemistry can turn sustainability requirements into real-world, scalable applications across the packaging and printing value chain.
• Next, we’ll examine how this move into bio-based ethyl acetate could influence Celanese’s investment narrative around sustainable materials and margins.

Outshine the giants: these 15 early-stage AI stocks could fund your retirement.

Celanese Investment Narrative Recap

To own Celanese, you need to believe its acetyls and engineered materials portfolio can translate cyclical recovery and sustainability trends into better margins and cash generation, despite recent underperformance and leverage concerns. The Siegwerk bio-based ethyl acetate deal fits that thesis, but on its own does not materially change the near term picture, where the key catalyst remains any sign of volume and pricing improvement and the biggest risk is prolonged margin pressure in oversupplied acetyl markets.

Among recent updates, the closure of the Ulsan engineered materials compounding facility and shift of production to China and India is especially relevant. It shows Celanese still reshaping its manufacturing footprint even as it grows bio-based partnerships, reinforcing that any upside from sustainable materials like bio-based ethyl acetate will sit alongside ongoing cost and capacity actions that matter for margins.

Yet behind the appeal of greener solvents, investors also need to be aware of prolonged acetyl overcapacity and what it could mean for...

Celanese's narrative projects $10.2 billion revenue and $799.9 million earnings by 2028.

Uncover how Celanese's forecasts yield a $51.50 fair value, a 4% upside to its current price.

Exploring Other Perspectives

While the Siegwerk partnership points to progress in sustainable solvents, the most cautious analysts still model only about US$10.0 billion of revenue and roughly US$862.3 million of earnings by 2029, so you should recognize that some see bio-based gains as only partly offsetting structural headwinds.

Explore 5 other fair value estimates on Celanese - why the stock might be worth just $51.50!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Celanese research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Celanese research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Celanese's overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 51 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.